Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BIO Suggests Re-Evaluation Of Continuous Marketing Application Programs

Executive Summary

FDA's continuous marketing application pilot programs may not be worth continuing, the Biotechnology Industry Organization suggested

You may also be interested in...



PDUFA Provides Opportunity For Conditional Approvals, Consumer Groups Say

Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act

PDUFA Provides Opportunity For Conditional Approvals, Consumer Groups Say

Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act

PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions

FDA is emphasizing the difficulties of industry requested meetings in its early public discussion of the 2007 Prescription Drug User Fee Act reauthorization

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS046566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel